Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin
✍ Scribed by Jaime Feliu; Luis López Gómez; Caterina Madroñal; Enrique Espinosa; Javier Espinosa; Carlos García Girón; Beatriz Martínez; Javier Castro; Isabel De la Gándara; Manuel González Barón; for the Oncopaz Cooperative Group
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 78 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND.
Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients. Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20 -30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life. In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.
METHODS.
Forty-nine patients with advanced NSCLC were included, 38 of whom were age Ն 70 years and 11 were age Ͻ 70 years but who had some contraindication to receiving cisplatin. All patients were evaluable for response and toxicity.
Treatment was comprised of VNB, 25 mg/m 2 , plus GEM, 1000 mg/m 2 , both on Days 1, 8, and 15 every 28 days. Patients received a minimum of three courses unless progressive disease was detected.